DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia
[Background]: Infants diagnosed with B cell acute lymphoblastic leukemia (B-ALL) and t(4;11) chromosomal rearrangement display poor therapeutic response, associated to the low expression of B lymphocyte factor HDAC7. This study was conceived to identify a therapeutic strategy for t(4;11) B-ALL that restores optimal HDAC7 expression., [Methods]: A multiomics approach in a large infant pro-B-ALL cohort was employed to identify HDAC7's repression mechanism. These data, combined with cell culture assays in a variety of pro-B-ALL cell lines with differential HDAC7 levels, led us to define a novel combination therapy. Murine leukemia models and ex vivo assays using patient-derived xenografts (PDX) were employed to assess the benefits of this therapy when incorporated to glucocorticoid-based chemotherapy., [Results]: Our data demonstrates that HDAC7 is epigenetically silenced by EZH2 and KMT2A::AFF1 fusion protein. Remarkably, the Menin-1 inhibitor MI-538 restores HDAC7 expression, and the effect is enhanced by class I HDAC inhibitor chidamide. This treatment drives leukemic pro-B cells towards a more differentiated state and impairs aberrant proliferation in an HDAC7-dependent manner. This newly identified therapy increases glucocorticoid sensitivity of PDX cells ex vivo, by repressing RUNX2 transcription factor. Finally, combining MI-538 and chidamide with standard chemotherapy reduces PDX cells engraftment in vivo and delays relapse., [Conclusions]: The combined therapy proposed, based on Menin-1 inhibition, improves t(4;11) B-ALL cells' response to standard therapy, an effect partially mediated by HDAC7 induction. Therefore, this novel therapy opens a new field for personalized treatments in high-risk leukemia, especially for infants presenting low expression of HDAC7 B cell factor., This work was supported by the Spanish Ministry of Science and Innovation (MICINN, EUR2019-103835), Instituto de Salud Carlos III (ISCIII, PI21/01451), Deutsche José Carreras Leukämie Stiftung (DJCLS/07R/2022) and elaborated at the Josep Carreras Leukaemia Research Institute (IJC, Badalona, Barcelona). This project was also supported by the Fight Kids Cancer Funding Programme (Cure2MLL project), supported by Imagine For Margo, Fondation KickCancer, Foundatioun Kriibskrank Kanner, Federazione Italiana Associazioni Genitori e Guariti Oncoematologia Pediatrica and Cris Cancer Foundation. We thank CERCA Programme/Generalitat de Catalunya for institutional support.
OdB was funded by a Postdoctoral Fellowship from the Asociación Española Contra el Cáncer (AECC) Foundation (POSTD20024DEBA) and by a Ramón y Cajal contract from the Spanish Ministry of Science, Innovation and Universities (RYC2021-031197-I). MG-V’s salary was funded by DJCLS/07R/2022 project. AM was funded by the Spanish Ministry of Science, Innovation and Universities, which is part of the Agencia Estatal de Investigación (AEI), through grant PRE2018-083183 (cofunded by the European Social Fund). JRT is supported by a Ramón y Cajal contract (RYC2021-031799-I) and the Asociación Galbán.
Research in PM laboratory is supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665); H2020 (101,057,250-CANCERNA), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and FEDER Funds, and CPP2021-008508, CPP2021-008676, CPP2022-009759 funded by MICIU/AEI/10.13039/501,100,011,033 and the European Union NextGenerationEU/PRTR); “Ayudas Merck de Investigación” from Health Merck Foundation; the Spanish Association Against Cancer (AECC, PRYGN234975MENE, PRYGN211192BUEN) and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). Additional funding was provided to CB by the Uno Entre Cien Mil Foundation, MINECO PLE2021-007518, Deutsche José Carreras Leukämie Stiftung (DJCLS/02R/2023) and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822 and PI24/00763)., Peer reviewed
Proyecto:
AEI EUR2019-103835